Skip to main content
Clinical Trials/NCT01713686
NCT01713686
Completed
Not Applicable

Prospective, Multi-center, Pivotal Trial Evaluating the Safety and Effectiveness of the Ulthera® System for Improvement in Lines and Wrinkles of the Décolletage

Ulthera, Inc4 sites in 1 country129 target enrollmentOctober 2012
ConditionsChest Wrinkles

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chest Wrinkles
Sponsor
Ulthera, Inc
Enrollment
129
Locations
4
Primary Endpoint
Percentage of Participants With a Reduction in Chest Wrinkles at 90 Days Post Treatment
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

This is prospective, multi-center clinical trial. Enrolled subjects will receive one Ulthera® treatment on the decolletage. Follow-up visits will occur at 90 and 180 days following treatment. Study images will be obtained pre-treatment, immediately post-treatment, and at each follow-up visit.

Registry
clinicaltrials.gov
Start Date
October 2012
End Date
August 2013
Last Updated
8 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Female, aged 35 to 70 years.
  • Subject in good health.
  • Moderate to severe skin lines and wrinkles on the décolletage; grade of ≥4 on a chest wrinkle scale.
  • Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period.
  • Willingness and ability to comply with protocol requirements.
  • Subjects of childbearing potential must have a negative urine pregnancy test result and must not be lactating.
  • Absence of physical conditions unacceptable to the investigator.
  • Willingness and ability to provide written consent for study-required photography.
  • Willingness and ability to provide written informed consent.

Exclusion Criteria

  • Presence of an active systemic or local skin disease that may affect wound healing.
  • Scarring in areas to be treated.
  • Tattoos in the areas to be treated.
  • Patients with ports or defibrillators.
  • Any open wounds or lesions in the area.
  • Active and severe inflammatory acne in the region to be treated.
  • Patients who have a history with keloid formation or hypertrophic scarring.
  • Inability to understand the protocol or to give informed consent.
  • Retinoid, microdermabrasion, or prescription level glycolic acid treatments to the décolletage area within two weeks prior to study participation or during the study.
  • Marked décolletage asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin.

Outcomes

Primary Outcomes

Percentage of Participants With a Reduction in Chest Wrinkles at 90 Days Post Treatment

Time Frame: 90 Days post-treatment

Assessment of improvement, in a blinded fashion, using a Chest Wrinkle Scale at 90 days post-treatment. However, during conduct of the trial, the Chest Wrinkle scale was deemed inadequate as a primary endpoint in this study. Therefore, conduct of a traditional blinded masked assessment, the gold-standard measure in aesthetics, was used as the primary endpoint,i.e., improvement in wrinkles and lines of the décolletage as determined by a blinded, masked, qualitative assessment of photographs at 90 days post-treatment compared to baseline. "Improvement" = a blinded evaluator assessed an "Improvement" when evaluating a masked, paired photo set and correctly chose the Post treatment photo. "Incorrect" = a blinded evaluator assessed an "Improvement" when evaluating a masked, paired photo set but incorrectly chose the Post treatment photo.

Percentage of Participants With a Reduction in Chest Wrinkles at 180 Days Post Treatment

Time Frame: 180 days post treatment

Assessment of improvement, in a blinded fashion, using a Chest Wrinkle Scale at 180 days post-treatment. However, during conduct of the trial, the Chest Wrinkle scale was deemed inadequate as a primary endpoint in this study. Therefore, conduct of a traditional blinded masked assessment, the gold-standard measure in aesthetics, was used as the primary endpoint, improvement in wrinkles and lines of the décolletage as determined by a blinded, masked, qualitative assessment of photographs at 180 days .post-treatment compared to baseline. "Improvement" = a blinded evaluator assessed an "Improvement" when evaluating a masked, paired photo set and correctly chose the Post treatment photo. "Incorrect" = a blinded evaluator assessed an "Improvement" when evaluating a masked, paired photo set but incorrectly chose the Post treatment photo.

Secondary Outcomes

  • Overall Aesthetic Improvement at 180 Days Post-treatment(180 days post-treatment)
  • Subject Satisfaction at 180 Days Post-treatment(180 days post-treatment)
  • Subject Satisfaction at 90 Days Post-treatment(90 days post-treatment)
  • Overall Aesthetic Improvement at 90 Days Post-treatment(90 days post-treatment)

Study Sites (4)

Loading locations...

Similar Trials